# Triple Negative Breast Neoplasms FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/triple-negative-breast-neoplasms

> 2 upcoming FDA catalysts in triple Negative Breast Neoplasms: KEYTRUDA® (pembrolizumab, MRK) on May to Aug 2030 (topline data readout); KEYTRUDA® (pembrolizumab, MRK) on May 2030 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| October 14, 2025 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Triple Negative Breast Neoplasms | completed | "NCT03036488 (Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-14 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-10-22." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03036488)) |
| March 2026 | [Truqap (capivasertib) primary completion](https://sec-api.dev/pdufa/capivasertib) | AZN | Triple Negative Breast Neoplasms | delayed | "NCT03997123 (Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-16 (ESTIMATED); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03997123)) |
| October 22, 2026 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Triple Negative Breast Neoplasms | completed | "NCT03036488 (Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-14 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-10-22." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03036488?tab=results)) |
| May to Aug 2030 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Triple Negative Breast Neoplasms | scheduled | "NCT06841354 (A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-05-18 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06841354)) |
| May 2030 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Triple Negative Breast Neoplasms | scheduled | "NCT06841354 (A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-05-18 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06841354)) |

## Drugs

- [KEYTRUDA® (pembrolizumab)](https://sec-api.dev/pdufa/pembrolizumab) (MRK)
- [Truqap (capivasertib)](https://sec-api.dev/pdufa/capivasertib) (AZN)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/triple-negative-breast-neoplasms.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Triple Negative Breast Neoplasms FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/triple-negative-breast-neoplasms

```bibtex
@misc{secapidev_indications_triple_negative_breast_neoplasms_20261116,
  title        = {Triple Negative Breast Neoplasms FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/triple-negative-breast-neoplasms}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_triple_negative_breast_neoplasms_20261116","title":"Triple Negative Breast Neoplasms FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/triple-negative-breast-neoplasms","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
